Spots Global Cancer Trial Database for parp
Every month we try and update this database with for parp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | NCT03911453 | Breast Cancer | Rucaparib | 21 Years - | University of Arizona | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | NCT05501548 | Prostate Cancer Castration-resi... | Olaparib Vitamin C | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| OSCA - Olaparib Standard of CAre Study | NCT02262273 | Platinum-sensit... | Data Collection | 18 Years - | AstraZeneca | |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | NCT01664000 | Solid Tumors | thioureidobutyr... | 18 Years - | Cellceutix Corporation | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | NCT04753879 | Metastatic Panc... | Nab-paclitaxel Gemcitabine Cisplatin Irinotecan Capecitabine Pembrolizumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | NCT02354131 | Ovarian Cancer | Niraparib Bevacizumab | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | NCT01589419 | Locally Advance... | veliparib capecitabine radiation | 18 Years - 99 Years | AbbVie | |
| Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | NCT02308072 | Head and Neck C... | Olaparib Cisplatin IMRT | 18 Years - | University College, London | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors | NCT02759666 | Neoplasm Solid Tumors | SHR3162 | 18 Years - | Atridia Pty Ltd. | |
| A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases | NCT00649207 | Brain Diseases Brain Neoplasms Central Nervous... Neoplasm Metast... Nervous System ... | ABT-888 Whole Brain Rad... | 18 Years - 99 Years | AbbVie | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | NCT02308072 | Head and Neck C... | Olaparib Cisplatin IMRT | 18 Years - | University College, London | |
| Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors | NCT01311713 | Solid Tumors | CEP-9722 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors | NCT01311713 | Solid Tumors | CEP-9722 | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | NCT03958045 | Small Cell Lung... | Rucaparib and N... | 18 Years - | University of Kentucky | |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | NCT05002868 | Solid Tumor Extensive-stage... Locally Advance... Metastatic Brea... Platinum-sensit... Platinum-Sensit... Platinum-Sensit... | RP12146 | 18 Years - | Rhizen Pharmaceuticals SA | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma | NCT00272415 | Melanoma | INO-1001 temozolomide | 18 Years - | Genentech, Inc. | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT01033292 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | NCT01033123 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| Advanced Refractory Solid Tumors With TP53 Mutations Register Study | NCT03927599 | Solid Tumor, Ad... | Data Collection | 18 Years - | Tianjin Medical University Second Hospital | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | Metastatic Brea... | Placebo Veliparib Carboplatin Temozolomide Paclitaxel | 18 Years - | AbbVie | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | NCT02855944 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Chemotherapy Rucaparib | 18 Years - | pharmaand GmbH | |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab | NCT06116578 | Cancer | Pembrolizumab Pembrolizumab a... Pembrolizumab a... | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT01033292 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | NCT01033123 | Ovarian Cancer | BSI-201 | 18 Years - | Sanofi | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | NCT02163694 | Metastatic Brea... | Veliparib Place... Veliparib Carboplatin Paclitaxel | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
